Patient characteristics and real-world treatment patterns in patients with early-stage triple-negative breast cancer receiving neoadjuvant chemotherapy

首页> 外文期刊>Intelligence: A Multidisciplinary Journal >Patient characteristics and real-world treatment patterns in patients with early-stage triple-negative breast cancer receiving neoadjuvant chemotherapy

【24h】

Patient characteristics and real-world treatment patterns in patients with early-stage triple-negative breast cancer receiving neoadjuvant chemotherapy

机译：患者患者特征和现实世界治疗模式，患者接受新辅助化疗的早期三阴性乳腺癌

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Intelligence: A Multidisciplinary Journal》 |2020年第2020期|共2页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类心理学;
关键词

相似文献

外文文献
中文文献
专利

1. Patient characteristics and real-world treatment patterns in patients with early-stage triple-negative breast cancer receiving neoadjuvant chemotherapy [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：患者患者特征和现实世界治疗模式，患者接受新辅助化疗的早期三阴性乳腺癌
2. A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial [J] . Blackwell Kimberly, Donskih Roman, Jones C. Michael, The oncologist . 2016,第7期

机译：拟议的生物仿制药LA-EP2006与参考培格非司亭预防早期乳腺癌接受骨髓抑制辅助或新辅助化疗的中性粒细胞减少症的比较：培格非司亭随机肿瘤治疗（支持治疗）以评估比较治疗（PROTECT-2），a第三阶段，随机双盲试验
3. A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial [J] . Kimberly Blackwell, Roman Donskih, C. Michael Jones, The oncologist . 2016,第7期

机译：拟议的生物仿制药LA-EP2006与参考培格非司亭用于预防早期接受骨髓抑制或新辅助化疗的乳腺癌中性粒细胞减少症的比较：培格非司亭随机肿瘤治疗（支持治疗）以评估比较治疗（PROTECT-2），a第三阶段，随机双盲试验
4. Breast MRI radiomics for the pre-treatment prediction of response to neoadjuvant chemotherapy in node-positive breast cancer patients [C] . Karen Drukker, Iman El-Bawab, Alexandra Edwards, SPIE Conference on Computer-Aided Diagnosis . 2019

机译：乳腺MRI辐射射清，用于节点阳性乳腺癌患者对新辅助化疗的反应预处理预测
5. Coregistration of serial breast MR studies for augmenting neoadjuvant chemotherapy response evaluation in breast cancer patients. [D] . Chittineni, Ruparani. 2008

机译：增强乳腺癌患者新系列辅助化疗反应评估的系列乳房MR研究的核心。
6. A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2) a Phase III Randomized Double-Blind Trial [O] . Kimberly Blackwell, Roman Donskih, C. Michael Jones, 2016

机译：拟议的生物仿制药LA-EP2006与参考培格非司亭预防早期乳腺癌接受骨髓抑制辅助或新辅助化疗的中性粒细胞减少症的比较：培格非司亭随机肿瘤治疗（支持治疗）以评估比较治疗（PROTECT-2）a第三阶段随机双盲试验
7. Demographic Characteristics and Treatment Patterns Among Patients Receiving Palbociclib for HR+/HER2− Advanced Breast Cancer: A Nationwide Real-World Experience [O] . Katalin Boér, Gábor Rubovszky, György Rokszin, 2021

机译：HR + / HER2晚期乳腺癌接受Palbociclib患者的人口特征和治疗模式：全国性的真实体验

Patient characteristics and real-world treatment patterns in patients with early-stage triple-negative breast cancer receiving neoadjuvant chemotherapy

著录项

相似文献

相关主题

期刊订阅